Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.

[This corrects the article DOI: 10.1021/acscentsci.0c00489.].

After publication of the original manuscript, we found that incorrect citations were used in two places in the manuscript in the section Development of Remdesivir. The correct citations with the full references below are as follows:

“The study by Warren et al. found that GS-5734 reduced EBOV replication in HeLa cells with an IC50 ≈ 100 nM, and it retained potency in in vivo nonhuman primate EBOV infection models, while GS-441524 was inactive.75,47 In addition to demonstrating activity against EBOV, Agostini et al. showed that remdesivir also had antiviral activity against several other viruses, including the coronavirus MERS, with an IC50 of 340 nM in vitro.46”

“In nonhuman primates, daily administration of 10 mg/kg of remdesivir yielded a short plasma half-life of the prodrug (t1/2= 0.39 h), but sustained intracellular levels of the triphosphate form.75”

(46) Agostini, M. L.; Andres, E. L.; Sims, A. C.; Graham, R. L.; Sheahan, T. P.; Lu, X.; Smith, E. C.; Case, J. B.; Feng, J. Y.; Jordan, R.; Ray, A. S.; Cihlar, T.; Siegel, D.; Mackman, R. L.; Clarke, M. O.; Baric, R. S.; Denison, M. R. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. .

(47) Madelain, V.; Baize, S.; Jacquot, F.; Reynard, S.; Fizet, A.; Barron, S.; Solas, C.; Lacarelle, B.; Carbonnelle, C.; Mentre, F.; Raoul, H.; de Lamballerie, X.; Guedj, J. Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. .

(75) Warren, T. K.; et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. .

We regret these oversights and apologize to the cited researchers for the incorrect citation of their work.